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Abstract
Selenium (Se) is an essential micronutrient that exerts its functions via selenoproteins. Little is known about the role of Se in
inflammatory bowel disease (IBD). Epidemiological studies have inversely correlated nutritional Se status with IBD severity
and colon cancer risk. Moreover, molecular studies have revealed that Se deficiency activates WNT signaling, a pathway
essential to intestinal stem cell programs and pivotal to injury recovery processes in IBD that is also activated in
inflammatory neoplastic transformation. In order to better understand the role of Se in epithelial injury and tumorigenesis
resulting from inflammatory stimuli, we examined colonic phenotypes in Se-deficient or -sufficient mice in response to
dextran sodium sulfate (DSS)-induced colitis, and azoxymethane (AOM) followed by cyclical administration of DSS,
respectively. In response to DSS alone, Se-deficient mice demonstrated increased morbidity, weight loss, stool scores, and
colonic injury with a concomitant increase in DNA damage and increases in inflammation-related cytokines. As there was an
increase in DNA damage as well as expression of several EGF and TGF-b pathway genes in response to inflammatory injury,
we sought to determine if tumorigenesis was altered in the setting of inflammatory carcinogenesis. Se-deficient mice
subjected to AOM/DSS treatment to model colitis-associated cancer (CAC) had increased tumor number, though not size, as
well as increased incidence of high grade dysplasia. This increase in tumor initiation was likely due to a general increase in
colonic DNA damage, as increased 8-OHdG staining was seen in Se-deficient tumors and adjacent, non-tumor mucosa.
Taken together, our results indicate that Se deficiency worsens experimental colitis and promotes tumor development and
progression in inflammatory carcinogenesis.
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Introduction
The essential micronutrient selenium (Se) is of fundamental
importance to human health. Se, through selenoproteins, has
antioxidant roles, influences immune activity, and its levels are
inversely correlated with cancer risk [1] and inflammatory bowel
disease (IBD) [2–4] In the case of IBD, red blood cell glutathione
peroxidase activity [5], a Se-dependent activity and mRNA levels
of Sepp1 [6], a selenoprotein, are reduced.
IBD is an autoimmune inflammatory disease of the GI tract
affecting as many as 1.4 million people in the United States [7].
IBD carries numerous and serious medical complications: stricture
and fistula formation, infection, severe pain, anemia, and
malnutrition [8–11]. The pathophysiology of IBD is thought to
be multifactorial in origin. Genetic, microbial, and environmental
factors have all been implicated, but the fundamental etiology
remains unclear. Nutritional deficiencies have been a major
concern in the management of IBD for decades and numerous
studies have documented decreased levels of Se in IBD compared
to control patients [12–15]. Moreover, as Se deficiencies are often
seen in IBD, downregulation of several selenoproteins have also
been identified. Serum selenoprotein P (Sepp1) levels are
significantly lower in patients with Crohn’s disease [6] and
glutathione peroxidase 1 mRNA is significantly downregulated in
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mononuclear cells from patients with IBD [16]. Defects in
epithelial integrity contribute to IBD pathogenesis and under-
standing mechanisms affecting epithelial homeostasis is a priority
[17]. In this regard, Se has been directly linked to WNT signaling
[18] and the intrinsic apoptosis pathway [19], suggesting that it
may play a role in epithelial integrity in response to injury.
Several epidemiological studies suggest that Se status is inversely
correlated with cancer incidence and mortality [20–23], but Se
supplementation trials failed to show benefit, possibly due to the
fact that the advantages of Se supplementation are dependent on
several factors including baseline Se status, genetic background
(e.g. the existence of polymorphisms in selenoprotein genes), type
of cancer, as well as the metabolic conversion and dose of Se
supplements [24]. Furthermore, several selenoproteins have been
correlated with cancer risk. Mutation of the selenocysteine transfer
RNA gene which results in decreased expression of some
selenoproteins results in reduction in murine colon cancer risk
[25]. More specifically, elevated glutathione peroxidase-2 (Gpx-2)
expression has been detected in colorectal adenomas [26–29].
Subsequently, double knockout of Gpx-1 and Gpx-2 leads to
bacterial-induced intestinal inflammation and, ultimately, ileal
tumor formation [30] and Gpx-2 decreases inflammation and
tumors in response to inflammatory carcinogenesis [31]. Expres-
sion levels of selenoproteins including Gpx-1, Gpx-3, and Sepp1
are significantly decreased in colorectal cancer, with lowered
Sepp1 expression correlating most significantly with tumor stage
[32]. As such, we have shown that Gpx-3 serves as a tumor
suppressor in the AOM/DSS model of CAC [33]. Thus, both
selenium and selenoproteins may play pivotal roles in tumor
modulation, especially in the setting of inflammatory carcinogen-
esis.
There may be sub-populations of CRC patients who would
benefit from Se supplementation. IBD may fall into this category
as it is characterized by chronic inflammation and oxidative stress
[34] and ulcerative colitis and Crohn’s colitis patients are at
increased risk for developing colon cancer [35]. Experimental
studies demonstrating that Se deficiency exacerbates intestinal
injury and tumorigenesis are not definitive. The aim of these
studies was to determine whether Se deficiency exacerbates colitis
and promotes inflammation-associated carcinogenesis. Mice were
rendered Se-deficient via maintenance on a tightly controlled Se-
deficient diet. Se-deficient mice had exacerbated colitis after DSS
injury, resulting in a pro-tumorigenic microenvironment with
increased cytokines, oxidative stress, and DNA damage. Further-
more, when inflammatory carcinogenesis modeling was per-
formed, Se-deficient mice had increased tumorigenicity and more
advanced lesions compared to Se-sufficient cohorts. Thus, Se
supplementation in Se-deficient IBD patients may protect from
mucosal injury and malignant degeneration.
Materials and Methods
Ethics Statement
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institute of Animal Care and Use
Committee at Vanderbilt University (protocol number: M/10-
355). Every effort was made to minimize suffering.
Murine DSS Morbidity and Inflammatory Carcinogenesis
Modeling
Experimental diets were Torula yeast-based and identical
except for their Se contents. The basal diet contained less than
0.01 mg Se per kg (Se-deficient) and the Se-sufficient diet was the
same diet supplemented with 0.25 mg Se as sodium selenite per kg.
Se-deficient and -sufficient diets were prepared and pelleted to our
specifications [36] by Harlan-Teklad (Madison, WI, USA). Upon
weaning, Wild-type (WT) C57BL/6 mice were maintained on the
experimental diets for 12 weeks prior to initiation of DSS or
AOM/DSS experiments to ensure Se deficiency.
DSS at a molecular weight of 40,000–50,000 was obtained from
USB Corporation (Cleveland, OH, USA). A single lot was used for
all experiments described in this publication. A 3% w/v DSS
solution was made in distilled water and filtered through a
0.22 mm cellulose acetate filter. This solution was then substituted
for animal drinking water and barriers were placed on the
automatic watering systems within each cage.
For the DSS morbidity experiments (results shown in Figures 1,
2, 3, 4), Se-sufficient (n = 15) and Se-deficient (n = 10) mice were
treated with DSS (Figure 1A) until their weight loss reached 20%
of their original weights, at which time they were sacrificed.
Animals were weighed daily and stools were examined for
consistency and the presence of blood. Stool consistency scores
ranged from 0–2, with 0= hard, normal stools, 1 = soft and spread,
2 = diarrhea-like. Presence of blood was scored with a 0= no
blood, 2= blood present, 4 = copious amounts of blood. Values
were added for each mouse.
For the murine inflammatory carcinogenesis protocol (results
shown in Figures 5–6), Se-sufficient (n = 18) or -deficient (n = 20)
C57BL/6 WT mice were injected with 12.5 mg/kg AOM (Sigma-
Aldrich) intraperitoneally as described in [33,37,38]. After a 3-day
recovery period, the animals were started on the first of 3 cycles of
3% DSS ad libitum (see schematic in Figure 5A). Each cycle was 4
days in length and was separated by a 16-day recovery period.
Eight days into each recovery period, murine endoscopy was
performed to monitor colitis severity and tumor burden [39]. After
the last cycle, animals were sacrificed following 26 days of
recovery. Mice were anesthetized with isofluorane prior to
exsanguination from the inferior vena cava. Blood was treated
with 15 ml of a 1 mg/ml solution of disodium EDTA to prevent
coagulation and plasma was separated by centrifugation for 2
minutes at 12,0006g. The colon was removed, flushed with PBS,
and opened longitudinally and gross tumor counts were conducted
using a dissecting microscope at 156 magnification and size
measurements obtained using digital calipers. Microscopic analysis
was conducted by an experienced gastrointestinal pathologist
(M.K. Washington) for dysplasia on H&E stained ‘‘Swiss rolled’’
colons (processed by the Vanderbilt Translational Pathology
Shared Resource core). Low-grade dysplasia (LGD) refers to
preinvasive pedunculated, sessile, or flat plaque-like lesions with
simple glandular outlines, without loss of cellularity polarity. High-
grade dysplasia (HGD) are adenomas with architectural complex-
ity, increased cytologic atypia, and loss of tumor cell polarity
[40,41]. Sections of tumor and normal adjacent colon were
collected and stored in RNAlater (Qiagen, Valencia, Santa
Clarita, California, USA) and a section of the most distal colon
above the anus was collected and flash frozen in liquid nitrogen for
protein analysis and/or determination of Se content. The
remainder of the colon was ‘‘Swiss Rolled’’, formalin fixed
overnight, and sectioned for histological analysis.
Colonic Selenium Measurements
The determination of colonic Se was carried out using a
modification of the fluorometric assay of Koh and Benson [42]
and Sheehan and Gao [43]. Briefly, tissue was digested in nitric
and perchloric acids and Se was complexed with diaminonaphtha-
lene. Selenium-diaminonaphthalene was extracted into cyclohex-
Se Deficiency Exacerbates Injury and Tumorigenesis
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Figure 1. Dietary selenium depletion reduces colon selenium levels and plasma glutathione peroxidase activity. A. Schematic for the
DSS morbidity protocol. At day 0, mice were weighed and then given a 3% DSS solution in lieu of drinking water. Each day, mice were weighed and
stools were obtained for analysis of blood and stool consistency (weight and stool analyses times indicated by black diamonds). Individual mice were
sacrificed if their weights fell below 80% of their original weights. B. Selenium sufficient (n = 7) and deficient (n = 7) colons were analyzed for selenium
concentrations. ***P,0.0001. C. Plasma glutathione peroxidase activity is quantified. ***P,0.0001.
doi:10.1371/journal.pone.0067845.g001
Figure 2. Selenium deficiency exacerbates colonic injury after DSS treatment. A. Se-sufficient (n = 15) and -deficient (n = 10) mice were
subjected to the DSS morbidity protocol (see Figure 1A) and percent survival was tracked. P=0.003, Log-rank (Mantel-Cox) test. B. Stool scores were
analyzed for Se-sufficient and -deficient mice on the DSS morbidity protocol. The graph depicts the average stool score for each dietary group on
each day of DSS administration. P,0.001, 2-way ANOVA. C. Percent of original weight averaged for each dietary group on each day of DSS
administration. P,0.01, 2-way ANOVA. D. Colitis damage scores (described in Materials and Methods) for each dietary group analyzed at the
completion of the experiment (left) and representative images of Swiss rolled colons from each group (right). Top and bottom of box 25th and 75th
percentile, bar represents the median value, whiskers minimum and maximum values. **P=0.006, Students-t test.
doi:10.1371/journal.pone.0067845.g002
Se Deficiency Exacerbates Injury and Tumorigenesis
PLOS ONE | www.plosone.org 3 July 2013 | Volume 8 | Issue 7 | e67845
ane and fluorescence was measured in a Perkin-Elmer LS 55
fluorometer.
Plasma Glutathione Peroxidase Activity Assay
Plasma collected from mice was subjected to a glutathione
peroxidase (Gpx) activity assay using a modified protocol [44]
based on the method of Paglia and Valentine [45]. In short, 800 ml
of reaction cocktail (50mmol/L potassium phosphate, pH 7.0,
1mmol/L EDTA, 1mmol/L NaN3, 0.2mmol/L glutathione) was
mixed with 10 ml plasma and 90 ml water in a clear plastic cuvette
and incubated at room temperature for 5 minutes. Next, 100 ml of
H2O2 substrate (0.25mmol/L H2O2 in H2O) was added to the
reaction mixture to initiate the reaction. Gpx activity was assessed
by measuring the rate of change of A340 during the linear phase of
the reaction. The rate of change was then converted to the
number of mmoles of NADPH oxidized/minute using the
extinction coefficient of 6.26103 L mol21 cm21 for NADPH at
340 nm. Blank reactions with distilled water were subtracted from
each assay.
F2-Isoprostane Analysis
DSS-treated mice (WT C57BL/6 fed Se-sufficient diets n= 3,
WT C57BL/6 fed Se-deficient diets n = 3, 3% DSS ad libitum for
3 days) were housed in metabolic cages and urine was collected for
12 hours on days 0 and 3 of DSS administration. Urinary F2-
isoprostanes were measured by stable isotope dilution gas
chromatography mass spectrometry using [2H4]15-F2t-isopros-
tane as internal standard as previously described [46]. Values were
normalized to mg creatinine in urine.
Histological Injury Analysis
A colitis damage score was generated from digital images of
H&E stained sections, by first measuring the distance around the
intact muscularis using AVP Universal Desktop Ruler software (as
performed by [47]). The areas of ulceration were then measured
and given scores of 1, 2, 3, or 4, where a score of 1 represents
injury involving the lower 1/3 of the crypt, 2 equaling injury to the
lower 2/3rds of the crypt, 3 equaling total crypt loss however the
epithelial lining remains intact and 4 equaling total crypt and
complete epithelial loss. The ulceration score was then multiplied
by the length of the involved colon, summed, and divided by the
total colon length to give a measure of ulceration severity/colon
length. Measurements were performed in a blinded fashion in all
colons from mice subjected to the DSS morbidity protocol.
Cytokine Array Analysis
RNA from Se-sufficient or -deficient DSS morbidity colons
(collected on day nine of DSS treatment) was isolated using the
Figure 3. Cytokine expression is aberrantly regulated in selenium deficient mice post-DSS. A. mRNA expression changes in Se-sufficient
(n = 4) and -deficient (n = 4) mice on from day nine of the DSS morbidity protocol. Genes were grouped based on pathways identified by PANTHER
pathway analysis software. Expression was normalized to Hprt. A. TGF-b pathway alterations include Bmp8b=bone morphogenetic protein 8b,
Gdf1 =Growth differentiation factor-1, Tgfb1= transforming growth factor beta-1, Tgfb2 = transforming growth factor beta-2. B. EGF pathway
alterations include Egf = epidermal growth factor, Igf1 = insulin-like growth factor 1, Nrg4=neuregulin 4. C. Developmental pathway alterations
include expression changes in Lta = lymphotoxin alpha, Efnb2= ephrin-B2, Efnb3= ephrin-B3, Fgf22 = fibroblast growth factor 22. D. The gene altered
within the group titled antioxidant activity is Tpo = thyroid peroxidase. E. Immune system process alterations are demonstrated in
Cxcl13 = chemokine (C-X-C motif) ligand 13, Ifnk = interferon kappa, Ctf1 = cardiotrophin 1, Ccl27 = chemokine (C-C motif) ligand 27,
Ccl20 = chemokine (C-C motif) ligand 20, IL17c = interleukin 17c, IL23a = interleukin 23a.-- *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0067845.g003
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RNeasy Mini Kit (Qiagen, Valencia, Santa Clarita, California,
USA). cDNA was synthesized using the iScript cDNA synthesis kit
(Bio-rad, Hercules, California, USA) from 1 mg of total RNA. 1 ml
of the 20 ml cDNA produced through the iScript reaction was used
as a template in each subsequent PCR reaction. SYBR green
qRT-PCR was performed using mouse cytokine array libraries I
(Cat #: MCA-I) and II (Cat #: MCA-II) purchased from
RealTimePrimers.com (Elkins Park, Pennsylvania, USA) accord-
ing to manufacturer’s instructions. Individual cytokines were
analyzed using the delta-delta Ct method and normalized to
Hypoxanthine-Guanine Phosphoribosyltransferase (Hprt). Those
showing significant differences were plotted using Graphpad
Prism. In order to develop the heat map, data was incorporated




Five-micrometer sections were cut, dewaxed, and hydrated.
Antigen retrieval was conducted using Antigen Unmasking
Reagent (Vector Laboratories, Inc., Burlingame, California,
USA) according to manufacturer’s instructions. After blocking,
primary antibody was added [a-Ki67 (NeoMarkers RB-1510-P,
Fremont, California, USA), 1:1,000; a-8-hydroxy-29deoxyguano-
sine (8-OHdG, Abcam ab26842, Cambridge, Massachusetts,
USA) 1:50] and incubated overnight at 4uC. Isotype-matched
antibodies were included as negative controls. Sections were then
incubated for one hour at room temperature in secondary
antibody (Ki67: Goat a-Rabbit-cy3, Invitrogen A10520; 8-
OHdG: a-mouse-FITC, Sigma F-0257). Identification of apoptot-
ic cells was conducted using the ApopTag Plus Peroxidase In Situ
Apoptosis Kit (Chemicon, Temecula, California, USA) according
to the manufacturer’s protocol. Control slides were obtained by
omitting the terminal transferase (TnT) enzyme. For immunoflu-
orescence staining of proliferation and DNA damage, slides were
Figure 4. Selenium deficiency induces oxidative stress as measured by F2-isoprostanes and DNA damage. A. Selenium-sufficient (n = 3,
white bars) and -deficient (n = 3, black bars) mice were given 3% DSS ad lib. and maintained in metabolic cages. Urine was collected at days 0 and 3 of
DSS administration and F2-isoprostanes were measured and normalized to mg of creatinine. *P= 0.05, 1-way ANOVA. B. 8-OHdG (FITC) staining was
performed in Se-sufficient (n = 12) and -deficient (n = 12) mice post-DSS morbidity protocol and quantified based on number of positive cells per
high-powered field (HPF, 40x) length (left). Representative staining is shown on the right. ***P,0.0001.
doi:10.1371/journal.pone.0067845.g004
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counterstained and mounted with ProLong Gold antifade
including 49,6-diamidino-2-phenylindole (DAPI, Invitrogen,
Grand Island, New York, USA). DNA damage indices were
generated by counting the number of positive cells per colon
length within each high-powered field, with 5 high-powered fields
counted per colon, starting at the most distal colon. Apoptosis, and
proliferation indices were generated by counting either the
number of positive cells per high-powered field (HPF; 40x
objective) within each tumor or the number of positive cells per
longitudinal crypt section in 20 crypts per mouse by a blinded
observer. The average score was then calculated for each Swiss-
rolled colon.
Statistical Methods
Differences between Se-deficient and -sufficient mice were
determined utilizing Graphpad Prism and analysis with the
Student’s t-test. The survival curve was analyzed using the Log-
rank (Mantel-Cox) test. Differences in stool scores and percentage
weight loss were determined using two-way ANOVA for repeated
measurements over time. Urine F2-isoprostane analysis of all four
groups was analyzed using one-way ANOVA with a Newman-
Keuls post-test to determine variances between columns. Finally,
statistical analysis of high-grade dysplasia was performed using the
Fisher’s Exact test.
Results
Dietary Selenium Maintains Epithelial Integrity
Se, through selenoproteins, has antioxidant roles, influences
immune activity, and has been inversely correlated with IBD
[4,48] and cancer risk [1]. Because oxidative stress compromises
mucosal integrity [49], and Se deficiency has been shown to
increase oxidative stress [50], we determined whether dietary Se
deficiency influences the severity of colitis following treatment with
3% DSS ad lib (Figure 1A). Animals were fed either Se-sufficient or
-deficient diets for 12 weeks, an extended period of time sufficient
to ensure Se deficiency which we confirmed via measurement of
colonic mucosal Se levels at the end of the DSS experiment
(333.1616.5 vs 60.664.1 ng/g, P,0.0001, Figure 1B) and plasma
glutathione peroxidase (Gpx) activity (215.4631.6 vs
18.9627.8 nmol NADPH/ml.min, P,0.0001, Figure 1C). In this
experiment, mice were maintained on 3% DSS until their weight
reached 80% of their original weights (survival endpoint). Se
deficient mice median survival was 9 days in comparison to Se
sufficient whose median survival was 12 days (P = 0.003,
Figure 2A). Additionally, Se deficient mice had worsened diarrhea
and increased blood in stools (stool scores at day 9:2.760.7 vs
5.760.3, P=0.02, Figure 2B), had accelerated weight loss
(84.361.2 vs 77.461.2% of starting body weight at day 9,
P=0.01, Figure 2C), and had more severe colitis/epithelial injury
(2.160.2 vs 2.960.1, P=0.006, Figure 2D). These results indicate
that Se is protective against DSS-induced colonic injury.
Pro-tumorigenic Microenvironment is Promoted by
Selenium Deficiency
Inflammation, a component of the epithelial and tumor
microenvironment, is a contributing factor that predisposes to
malignancy and, as we had observed increased injury in response
to DSS administration in Se-deficient mice, we wanted to
determine whether chemokine and cytokine signaling was
Figure 5. Selenium protects against tumor initiation and progression in inflammatory carcinogenesis. A. Schematic of the AOM/DSS
CAC protocol. Mice are injected with AOM 4 days prior to beginning the first of three 4-day cycles of DSS. There are 16 days between each DSS cycle
and mice are sacrificed 26 days after their last cycle of DSS. Black circles indicate periods at which mice are endoscopically analyzed. B. Selenium
sufficient (n = 18) and deficient (n = 20) mice were subjected to the AOM/DSS protocol and tumor number was analyzed. ***P=0.0002. C. Tumors
were analyzed (by pathologist M.K. Washington) for dysplasia grade (LGD= low-grade dysplasia, HGD=high-grade dysplasia) and quantified based
on percent of tumors demonstrating each grade (left, HGD ***P,0.0001, Fisher’s exact test). Representative H&E stained colons are displayed on the
right.
doi:10.1371/journal.pone.0067845.g005
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aberrantly regulated in Se-deficient mice in response to injury.
Therefore, we analyzed Se-sufficient and -deficient colons for
cytokine mRNA expression using a mouse cytokine array. Because
the RNA isolated for analysis was isolated from whole colon, the
source of these cytokines and chemokines would include epithelial
and stromal components. This analysis yielded alterations in
several chemokines and cytokines that are displayed as a heat map
for all genes tested (Figure S1A and B). Significantly altered
cytokines were grouped according to function using PANTHER
Pathway Analysis software [51]. Transforming growth factor beta
(TGF-b) signaling was altered with increased Tgf-b1 and -b2
transcripts and decreased growth differentiation factor-1 (Gdf1)
and bone morphogenetic protein 8b (Bmp8b) (Figure 3A).
Additionally, the EGF pathway was altered (Figure 3B), as were
components of developmental programs (Figure 3C). Levels of
thyroid peroxidase (Tpo), PANTHER classified as an antioxidant,
was increased (0.0160.003 vs 9.166.3 fold change, P = 0.04,
Figure 3D), consistent with a decrease in Se leading to aberrant
regulation of thyroid hormone production [52]. Supporting
immune system process activation there was increased chemokine
(C-X-C motif) ligand 13 (Cxcl13), interferon kappa (Ifnk),
cardiotrophin 1 (Ctf1), chemokine (C-C motif) ligand 27 (Ccl27),
chemokine (C-C motif) ligand 20 (Ccl20), interleukin 17c (Il-17c),
and interleukin 23a (Il-23a) messenger RNA in Se-deficient states
(Figure 3E). Collectively, multiple factors capable of promoting
tumor development were upregulated after DSS treatment in a Se-
deficient state.
Lipid Peroxidation, a Marker of Oxidative Stress, is
Increased in the Urine of Selenium-deficient mice after
DSS Induced Colitis
DSS administration in the drinking water causes colonic
epithelial injury and a robust innate inflammatory response
producing an environment enriched in reactive oxygen and
Figure 6. Selenium deficient colons demonstrate increased intratumoral proliferation and DNA damage in response to
inflammatory carcinogenesis. Swiss-rolled colons of Se-sufficient and –deficient mice post-AOM/DSS protocol were analyzed for proliferation
and DNA damage. A. Ki67 immunohistochemistry was conducted to identify actively proliferating cells. Intratumoral proliferation index calculated
from number of Ki67-positive cells per HPF (top, Se-sufficient n = 15, Se-deficient n = 20, 406). B. Immunofluorescence for 8-OHdG was conducted
according to Materials and Methods. Staining is quantified per longitudinal crypt section in 20 crypts of each mouse (top) and representative images
are shown (bottom). C. 8-OHdG staining is quantified per tumor HPF (top, Se-sufficient n = 19, Se-deficient n = 20, 406) and representative images are
shown (bottom). **P=0.009, ***P,0.0001.
doi:10.1371/journal.pone.0067845.g006
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nitrogen species [53]. Oxidative injury is quantifiable by
measuring F2-isoprostanes (F2-IsoPs), one of the most reliable
measures of in vivo lipid peroxidation, a marker of oxidative stress
[46,54]. We measured F2-IsoPs using stable isotope dilution gas
chromatography mass spectrometry methodology. F2-IsoP levels
were not different at baseline between Se-sufficient and -deficient
mice (0 time point, Figure 4A). However, increased urine F2-IsoPs
were observed in mice fed a Se-deficient diet when compared to
mice on a Se-sufficient diet, after 3 days of 3% DSS (6.060.3 vs
9.161.0 ng/mg creatinine, P= 0.05, Figure 4A), indicating that
Se protects from lipid peroxidation in this model. Therefore, F2-
IsoPs effectively quantitate oxidative stress levels in the DSS model
and Se-deficiency increases whole animal oxidative stress after
DSS-induced injury.
DNA Damage is Increased in Selenium-deficient mice in
Response to DSS
As inflammatory injury and lipid peroxidation were upregulated
in Se-deficient mice, and because Se has been linked with DNA
damage repair [55,56], we next determined whether DNA
damage was increased in these mice. Colonic epithelial 8-OHdG
staining, which identifies oxidative damage to DNA, was
significantly increased in Se-deficient mice after DSS injury
(13.261.3 vs 28.861.6 8-OHdG+ cells/HPF length, P,0.0001,
Figure 4B). Thus, Se-deficiency exacerbated colitis and was
associated with increased pro-inflammatory and pro-tumorigenic
cytokines and increased DNA damage. These changes collectively
produce a microenvironment primed for tumorigenesis.
Dietary Selenium Protects from Inflammatory
Carcinogenesis
Because Se deficiency promoted an activated pro-tumorigenic
microenvironment and DNA damage after DSS treatment, we
next determined if Se status modified inflammatory carcinogen-
esis. AOM is a procarcinogen that is metabolically activated to a
potent alkylating agent forming O6-methyl-guanine [57]. Its
oncogenic potential is markedly augmented in the setting of
chronic inflammation, such as that induced by repeated cycles of
DSS treatment [58,59].
To determine if dietary Se modifies CAC, we modeled
inflammatory carcinogenesis in Se-deficient or –sufficient
C57BL/6 mice using AOM/DSS (Figure 5A). There were no
significant changes in weight loss or DSS consumption during the
course of this experiment (Figure S2D and E). At necropsy, Se-
deficient mice demonstrated increased tumor multiplicity (3.460.4
vs 7.660.9 tumors/mouse, P = 0.0002, Figure 5B) as well as a
higher degree of dysplasia (P,0.0001, Figure 5C) compared to Se-
sufficient mice. Consistent with the morbidity studies (Figure 2),
there was an increase in morbidity in Se-deficient mice in response
to the AOM/DSS protocol (Figure S2A), though this difference
was not statistically significant. We did not detect alterations in
colon weight or length, however, suggesting that Se-deficient mice
did not sustain chronic inflammatory changes in response to the
AOM/DSS protocol (Figure S2B and C), at least when evaluated
after the 26-day recovery period. Taken together, these data
suggest that Se serves as a tumor suppressor that exerts its
influence at the levels of tumor initiation and progression.
Selenium Deficiency Results in Increased Intratumoral
Proliferation and a General Increase in DNA Damage
Several selenoproteins have been identified as direct WNT
targets [60] and Se deficiency activates WNT signaling [18],
implicating Se deficiency in a proliferation pathway that is
aberrantly regulated in colorectal cancer. Furthermore, mitochon-
drial selenoproteins have been implicated in the regulation of
mitochondrial-dependent cell death [19]. As we noted an increase
in tumor number in Se-deficient mice, we determined whether
cellular proliferation or apoptosis indices were altered. Prolifera-
tion, as measured by Ki67 staining, was increased in the tumors of
Se-deficient mice (26.061.9 vs 39.562.9 Ki67+ cells/tumor HPF,
P= 0.0008, Figure 6A), but not within colonic crypts (Figure S3A).
Apoptosis was quantified by TUNEL staining and no difference
was seen between the two groups (Figure S3B and C).
Interestingly, an increase in intratumoral proliferation is generally
associated with an increase in tumor size and not number. For this
reason, and due to the fact that DSS results in DNA damage
[33,61] which can lead to changes in the initiation frequency, we
stained crypts and tumors of Se-sufficient and -deficient mice with
8-OHdG. Consistent with what was observed in the DSS
morbidity study, Se deficiency led to a significant increase in
DNA damage within crypts (0.8360.04 vs 1.160.08 8-OHdG+/
crypt, P= 0.009, Figure 6B), as well as tumors (23.761.5 vs
46.863.7 8-OHdG+/tumor HPF, P,0.0001, Figure 6C). Indi-
cating augmented DNA damage, potentially contributing to the
increased tumorigenesis observed in Se-deficient mice.
Discussion
The essential trace element Se may be useful for the prevention
and/or abrogation of several diseases related to oxidative stress
including neurodegenerative, cardiovascular diseases [62]. In these
diseases, Se deficiency is uncommon and thus therapeutic
approaches targeting Se would require supranutritional amounts
of Se for treatment. This point is important because harmful side-
effects of supranutritional Se have been identified including
increased risk for diabetes [63]. In contrast, IBD is a disease
characterized by chronic inflammation, high oxidative stress and
Se deficiency making it a potential target for Se supplementation,
with the goal being to restore Se nutritional status to the normal
range. In support of this concept, our results demonstrate that, in
fact, Se sufficiency protects against DSS-induced injury when
compared to Se deficiency as morbidity, weight loss, and mucosal
injury in response to DSS were all significantly increased in mice
fed a Se-deficient diet. Moreover, Se may protect against mucosal
injury by decreasing expression of pro-inflammatory cytokines; as
such we detected increased mRNA expression of the B cell
chemoattractant chemokine (C-X-C motif) ligand 13 (Cxcl13), the
T cell inflammation associated Chemokine (C-C motif) ligand 27
(Ccl27), the lymphocyte chemoattractant Chemokine (C-C motif)
ligand 20 (Ccl20), as well as interleukin (Il)-17c which can promote
Th17 cell responses [64]. Of particular interest is the upregulation
of Il-23a, as Il-23 has been shown to be a pro-inflammatory factor
and target protein for inhibitory therapy in Crohn’s disease, since
it has major effects on Th17 cell differentiation [65]. These data
suggest that restoration of normal Se levels may be a therapeutic
option in IBD.
DSS-induced colonic injury, like ulcerative colitis, results in
increased oxidative stress, which is at least partly attributable to
immune cell infiltration and the release of inflammatory mediators
[66,67]. One method to quantify oxidative injury is to assess lipid
peroxidation via measurement of F2-isoprostanes (F2-IsoPs), non-
enzymatic derivatives of arachidonic acid [46]. It is important to
note that, although lipid peroxidation is an indirect measure of
oxidative stress, the Biomarkers of Oxidative Stress Study (BOSS)
identified F2-IsoPs as the most reliable index of in vivo oxidative
stress when compared against other known biomarkers [54].
Other labs have demonstrated increased F2-IsoPs in response to
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DSS using the Cayman assay [68,69]. We utilized stable isotope
dilution gas chromatography mass spectrometry analysis of F2-
IsoPs to demonstrate that Se deficiency further augments the
effects of DSS, indicating that DSS-induced lipid peroxidation, an
indicator of oxidative injury, is increased in response to Se
deficiency upon DSS administration and implicating Se in
protection from lipid peroxidation in the DSS model.
Chronic inflammation and cyclic epithelial injury characteristic
of IBD results in increased cancer risk, although the magnitude of
this risk is unclear [35]. In our studies we found that Se deficiency
leads to increased colonic injury and inflammation. Additionally,
several TGF-b signaling components were aberrantly expressed in
Se-deficient mice after DSS treatment. Transcripts for bone
morphogenetic protein 8b (Bmp8b), which important for primor-
dial germ cell determination [70], and a second TGF-b family
member, growth differentiation factor 1 (Gdf1), were downregu-
lated in DSS-treated Se-deficient mice. Gdf1 is correspondingly
underexpressed in salivary gland adenoid cystic carcinoma [71]
suggesting a potential role as a tumor suppressor. Furthermore,
Tgf-b1 gene expression is upregulated in Se-deficient mice and has
been implicated in the pathogenesis of colorectal neoplasia and
several polymorphisms have been identified in colorectal adenoma
which lead to Tgf-b1 overexpression [72,73]. Tgf-b2, also
identified as overexpressed in Se-deficient mice, has been linked
with tumor promotion as it is upregulated in colorectal, breast,
pancreatic, and brain cancer [74].
Transcripts of the EGF pathway are also upregulated in Se-
deficient mice with pathway members including epidermal growth
factor (Egf), insulin-like growth factor 1 (Igf1) and neuregulin 4
(Nrg4) all demonstrating increased expression in Se-deficient
compared to -sufficient mice subjected to the DSS morbidity
protocol. EGF is upregulated nearly 3-fold in colorectal carcinoma
[75] and the EGF signaling pathway is intimately linked to
promotion of solid tumor growth [76]. These data coupled with
the fact that we also see increased expression of the ephrins Efnb2
and Efnb3, which are known to contribute to tumor promotion as
well as progression [77], suggest that the signaling cascades and
inflammation resulting from Se deficiency after DSS injury may
result in increased cancer risk.
Beyond activation of oncogenic signaling pathways, Se
deficiency may promote tumorigenesis via affecting genomic
integrity [55]. Supplementation with moderate levels of Se
compounds both in vivo and in vitro is thought to protect against
the formation of DNA adducts and maintain chromosomal
stability and telomere length and function [56]. In support of this
we found that Se deficiency did, in fact, increase DNA adduct
formation, a marker of DNA damage, after DSS-induced colonic
stress, suggesting another mechanism by which Se might inhibit
tumorigenesis in CAC.
Two prior studies report on the effects of reduced dietary Se in
inflammatory colon tumorigenesis. Both have demonstrated a
subtle, non-significant, increase in tumorigenesis with decreased
dietary selenium [31,78]. There are several potential explanations
for why we observed a significant increase in tumor burden in our
studies; 1) Differences in model selection, 2) strain of mice studied,
and 3) degree and magnitude of Se deficiency. Our mice were fed
Se-deficient diets (less than 0.01 mg Se/kg) for 12 weeks prior to
the initiation of our protocols. This extensive time-frame was
selected because our group has previously determined that this will
ensure Se deficiency [79]. In our current studies we confirmed Se
deficiency by measuring plasma Gpx activity and colonic Se levels.
In contrast, the prior studies used low Se diets (0.02 and 0.086 mg
Se/kg, respectively) for shorter time periods before protocol
initiation. Our AOM/DSS protocol employs a single injection of
AOM followed by cyclical administration of 3% DSS. Using this
protocol, we achieved a tumor penetrance of 100% revealing a
significant role of Se deficiency in inflammatory carcinogenesis.
Furthermore, our data suggest that Se may also protect from
tumor progression as more advanced lesions occurred in the
setting of Se deficiency.
There is considerable epidemiological evidence indicating that
Se levels and cancer are inversely correlated [20,22–24]. Dietary
intervention studies targeting Se have been inconsistent, however.
Our findings suggest that Se supplementation, as a therapeutic
intervention, should be targeted to patient populations, or
individual patients, with demonstrable selenium deficiency.
Importantly, our data indicate that patients with IBD, a disease
in which Se deficiency occurs, might benefit from Se supplemen-
tation to prevent CAC. Beyond IBD and CAC, there needs to be a
concerted effort towards fully understanding the molecular basis
for how Se protects from tumorigenesis, in what cancers Se is
important, at what dietary levels Se is most beneficial, and in
which patient populations selenium supplementation might have a
beneficial impact.
Supporting Information
Figure S1 Cytokines are aberrantly regulated in sele-
niumdeficient mice subjected to DSS. A. Heat map of
mouse cytokine library I and B. mouse cytokine library II gene
expression in Se-deficient (n = 4) versus -sufficient (control, n = 4)
colons post-DSS morbidity (left) and a chart of represented
cytokines (right). Green =underexpression, Red= overexpression
where intensity of color indicates increasing distance from 0;
Grey = qRT-PCR yields were undetectable.
(TIF)
Figure S2 Selenium levels do not significantly impact
survival, colon weight, colon length, or mouse weight in
response to AOM/DSS. A. Survival curve of Se-deficient and -
sufficient mice in response to the AOM/DSS protocol. B. Colon
weight (g) and C. colon length (mm) post-AOM/DSS protocol. D.
Mouse weight (g) throughout the AOM/DSS protocol measured
on days 0, 1, 3, 4, and 7 of DSS administration during each DSS
cycle. E. DSS consumption/mouse during the four days of DSS
administration.
(TIF)
Figure S3 Crypt proliferation and crypt and tumor
apoptosis are unaltered in dietary models in response to
AOM/DSS. A. Quantification of Ki67 staining within crypts in
non-tumor bearing areas of Se-sufficient and -deficient mice. 20
crypts were counted for each mouse. B. Crypt and C. intratumoral
TUNEL counts in Se-sufficient and -deficient mice.
(TIF)
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